Ikeda Fumiaki
Post Marketing Product Development, Astellas Pharma Inc., Osaka, Japan.
Nihon Ishinkin Gakkai Zasshi. 2005;46(4):217-22. doi: 10.3314/jjmm.46.217.
Micafungin (MCFG) is a new lipopeptide antifungal agent of the echinocandin class. MCFG inhibits 1,3-beta-D-glucan synthesis in C. albicans and A. fumigatus in a non-competitive manner, and has antifungal activity against both Aspergillus and Candida species. In neutropenic mouse models of disseminated candidiasis and pulmonary aspergillosis, the efficacy of MCFG was superior to that of fluconazole and itraconazole, but comparable to that of amphotericin B. The efficacy and safety of MCFG were investigated in 70 patients with deep-seated mycosis caused by Candida and Aspergillus species. The overall clinical response rates were 57.1% in aspergillosis and 78.6% in candidiasis. The incidence of adverse events related to micafungin was 17.9%, and there was no dose-related occurrence of any adverse events. The results from this study indicated that micafungin was effective in aspergillosis and candidiasis, with no tolerability problems.
米卡芬净（MCFG）是一种新型的棘白菌素类脂肽抗真菌药物。米卡芬净以非竞争性方式抑制白色念珠菌和烟曲霉中的1,3-β-D-葡聚糖合成，并且对曲霉属和念珠菌属均具有抗真菌活性。在播散性念珠菌病和肺曲霉病的中性粒细胞减少小鼠模型中，米卡芬净的疗效优于氟康唑和伊曲康唑，但与两性霉素B相当。对70例由念珠菌属和曲霉属引起的深部真菌病患者研究了米卡芬净的疗效和安全性。曲霉病的总体临床缓解率为57.1%，念珠菌病为78.6%。与米卡芬净相关的不良事件发生率为17.9%，且未出现任何与剂量相关的不良事件。本研究结果表明，米卡芬净对曲霉病和念珠菌病有效，且不存在耐受性问题。
